Teva, Lilly and Amgen join battle for new $8bn migraine prevention market

New biologicals targeting the CGRP pathway could prove to be the biggest thing to hit the migraine market since the triptans in the 1990s, mid-stage data presented at the recent American Headache Society meeting in Washington suggest.

New biologicals targeting the CGRP pathway could prove to be the biggest thing to hit the migraine market since the triptans in the 1990s, mid-stage data presented at the recent American Headache Society meeting in Washington suggest.

The Washington DC meeting heard new Phase IIb data from two products from Teva and Lilly, TEV-48125 and LY2951742, together...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category